Miia Turpeinen

Summary

Affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Country: Germany

Publications

  1. ncbi A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes
    Miia Turpeinen
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Drug Metab Dispos 37:1017-24. 2009
  2. ncbi Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
    Ulrich M Zanger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
    Anal Bioanal Chem 392:1093-108. 2008
  3. ncbi Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation
    Ana M Gomes
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Pharmacogenomics 10:579-99. 2009
  4. ncbi Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
    Kathrin Klein
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tuebingen Stuttgart, Germany
    Front Pharmacol 1:129. 2010

Collaborators

Detail Information

Publications4

  1. ncbi A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes
    Miia Turpeinen
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Drug Metab Dispos 37:1017-24. 2009
    ..Taken together, these studies indicate that the formation of the active metabolite of nabumetone, 6-MNA, is predominantly catalyzed by CYP1A2 in HLMs with only minor contribution of other P450s...
  2. ncbi Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
    Ulrich M Zanger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
    Anal Bioanal Chem 392:1093-108. 2008
    ..In this review, we provide an up-to-date summary of the functional polymorphisms and aspects of the functional genomics of the major human drug-metabolizing cytochrome P450s, as well as their clinical significance...
  3. ncbi Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation
    Ana M Gomes
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Pharmacogenomics 10:579-99. 2009
    ..We investigated genetic and nongenetic POR variability and its impact on drug-oxidation activities in human liver microsomes...
  4. ncbi Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
    Kathrin Klein
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tuebingen Stuttgart, Germany
    Front Pharmacol 1:129. 2010
    ..In conclusion, we identified novel trans-associations between regulatory genes and hepatic CYP1A2 function and expression, but additional genetic factors must be assumed to explain the full extent of CYP1A2 heritability...